Analysis of CYP1B1 Polymorphisms in Lung Cancer Patients Using Novel, Quick and Easy Methods Based on CAPS and ACRS-PCR Techniques
Abstract
:1. Introduction
2. Results
2.1. Diagnosis of Polymorphism in the CYP1B1 Gene
2.1.1. c. 142C > G
2.1.2. c. 355G > T
2.1.3. c. 1294C > G
2.1.4. c. 1358A > G
2.2. Frequency of Occurrence of Individual Polymorphisms in the Analyzed Population of Lung Cancer Patients
2.3. Statistical Analysis between the Presence of SNPs and the Type and Stage of Cancer
3. Discussion
4. Materials and Methods
4.1. Clinical Samples
4.2. DNA Isolation
4.3. Determination of Polymorphism in CYP1B1 Gene
4.3.1. c. 142C > G
4.3.2. c. 355G > T, c. 1294C > G and c. 1358A > G
4.4. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Danielson, P.B. The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 2002, 3, 561–597. [Google Scholar] [CrossRef] [PubMed]
- Pelkonen, O.; Turpeinen, M.; Hakkola, J.; Honkakoski, P.; Hukkanen, J.; Raunio, H. Inhibition and induction of human cytochrome P450 enzymes: Current status. Arch. Toxicol. 2008, 82, 667–715. [Google Scholar] [PubMed]
- Liu, Y.-T.; Hao, H.-P.; Liu, C.-X.; Wang, G.-J.; Xie, H.-G. Drugs as CYP3A probes, inducers and inhibitors. Drug Metab. Rev. 2007, 39, 699–721. [Google Scholar] [CrossRef] [PubMed]
- Cheever, M.A.; Allison, J.P.; Ferris, A.S.; Finn, O.J.; Hastings, B.M.; Hecht, T.T.; Mellman, I.; Prindiville, S.A.; Viner, J.L.; Weiner, L.M.; et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 2009, 15, 5323–5337. [Google Scholar] [CrossRef] [PubMed]
- Tang, Y.M.; Wo, Y.Y.; Stewart, J.; Hawkins, A.L.; Griffin, C.A.; Sutter, T.R.; Greenlee, W.F. Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J. Biol. Chem. 1996, 271, 28324–28330. [Google Scholar] [CrossRef] [PubMed]
- Murray, G.I.; Melvin, W.T.; Greenlee, W.F.; Burke, M.D. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 297–316. [Google Scholar] [CrossRef] [PubMed]
- Matyjasik, J.; Cybulski, C.; Masojć, B.; Jakubowska, A.; Serrano-Fernandez, P.; Górski, B.; Dębniak, T.; Huzarski, T.; Byrski, T.; Gronwald, J.; et al. CYP1B1 and predisposition to breast cancer in Poland. Breast Cancer Res. Treat. 2007, 106, 383–388. [Google Scholar] [CrossRef] [PubMed]
- Stoilov, I.; Akarsu, A.N.; Alozie, I.; Child, A.; Barsoum-Homsy, M.; Turacli, M.E.; Or, M.; Lewis, R.A.; Ozdemir, N.; Brice, G.; et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am. J. Hum. Genet. 1998, 62, 573–584. [Google Scholar] [CrossRef]
- Church, T.R.; Haznadar, M.; Geisser, M.S.; Anderson, K.E.; Caporaso, N.E.; Le, C.; Abdullah, S.B.; Hecht, S.S.; Oken, M.M.; Van Ness, B. Interaction of CYP1B1, cigarette-smoke carcinogen metabolism, and lung cancer risk. Int. J. Mol. Epidemiol. Genet. 2010, 1, 295–309. [Google Scholar]
- Cote, M.L.; Wenzlaff, A.S.; Bock, C.H.; Land, S.J.; Santer, S.K.; Schwartz, D.R.; Schwartz, A.G. Combinations of cytochrome P-450 genotypes and risk of early-onset lung cancer in Caucasians and African Americans: A population-based study. Lung Cancer 2007, 55, 255–262. [Google Scholar] [CrossRef]
- Cote, M.L.; Yoo, W.; Wenzlaff, A.S.; Prysak, G.M.; Santer, S.K.; Claeys, G.B.; Van Dyke, A.L.; Land, S.J.; Schwartz, A.G. Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis 2009, 30, 626–635. [Google Scholar] [CrossRef] [PubMed]
- Shah, P.P.; Singh, A.P.; Singh, M.; Mathur, N.; Mishra, B.N.; Pant, M.C.; Parmar, D. Association of functionally important polymorphisms in cytochrome P4501B1 with lung cancer. Mutat. Res. 2008, 643, 4–10. [Google Scholar] [CrossRef] [PubMed]
- Timofeeva, M.N.; Kropp, S.; Sauter, W.; Beckmann, L.; Rosenberger, A.; Illig, T.; Jäger, B.; Mittelstrass, K.; Dienemann, H.; LUCY-Consortium; et al. CYP450 polymorphisms as risk factors for early-onset lung cancer: Gender-specific differences. Carcinogenesis 2009, 30, 1161–1169. [Google Scholar] [CrossRef]
- Watanabe, J.; Shimada, T.; Gillam, E.M.; Ikuta, T.; Suemasu, K.; Higashi, Y.; Gotoh, O.; Kawajiri, K. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 2000, 10, 25–33. [Google Scholar] [CrossRef] [PubMed]
- Wenzlaff, A.S.; Cote, M.L.; Bock, C.H.; Land, S.J.; Santer, S.K.; Schwartz, D.R.; Schwartz, A.G. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: A population-based study. Carcinogenesis 2005, 26, 2207–2212. [Google Scholar] [CrossRef] [PubMed]
- Bade, B.C.; Dela Cruz, C.S. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin. Chest Med. 2020, 41, 1–24. [Google Scholar] [CrossRef]
- Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001, 94, 153–156. [Google Scholar] [CrossRef] [PubMed]
- Shimada, T.; Fujii-Kuriyama, Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer 2005, 95, 1–6. [Google Scholar]
- Dąbrowski, A.; Ułaszewski, S.; Niedźwiecka, K. Rapid and easy detection of the five most common founder mutations in BRCA1 and BRCA2 genes in the Polish population using CAPS and ACRS-PCR methods. Acta Biochim. Pol. 2019, 66, 33–37. [Google Scholar] [PubMed]
- Benusiglio, P.R.; Fallet, V.; Sanchis-Borja, M.; Coulet, F.; Cadranel, J. Lung cancer is also a hereditary disease. Eur. Respir. Rev. 2021, 30, 210045. [Google Scholar] [CrossRef]
- De Iuliis, F.; Salerno, G.; Taglieri, L.; Scarpa, S. Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review. Cancer Chemother. Pharmacol. 2015, 76, 679–690. [Google Scholar] [CrossRef] [PubMed]
- Huang, R.S.; Duan, S.; Kistner, E.O.; Bleibel, W.K.; Delaney, S.M.; Fackenthal, D.L.; Das, S.; Dolan, M.E. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008, 68, 3161–3168. [Google Scholar] [CrossRef] [PubMed]
- McFadyen, M.C.; McLeod, H.L.; Jackson, F.C.; Melvin, W.T.; Doehmer, J.; Murray, G.I. Cytochrome P450 CYP1B1 protein expression: A novel mechanism of anticancer drug resistance. Biochem. Pharmacol. 2001, 62, 207–212. [Google Scholar] [CrossRef] [PubMed]
- Sissung, T.M.; Danesi, R.; Price, D.K.; Steinberg, S.M.; de Wit, R.; Zahid, M.; Gaikwad, N.; Cavalieri, E.; Dahut, W.L.; Sackett, D.L.; et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol. Cancer Ther. 2008, 7, 19–26. [Google Scholar] [CrossRef] [PubMed]
- Lao, X.; Qin, X.; Peng, Q.; Chen, Z.; Lu, Y.; Liu, Y.; Li, S. Association of CYP1B1 Leu432Val polymorphism and lung cancer risk: An updated meta-analysis. Lung 2014, 192, 739–748. [Google Scholar] [CrossRef] [PubMed]
- Helmig, S.; Wenzel, S.; Maxeiner, H.; Schneider, J. CYP1B1 mRNA inducibility due to benzo(a)pyrene is modified by the CYP1B1 L432V gene polymorphism. Mutagenesis 2014, 29, 237–240. [Google Scholar] [CrossRef]
- Hosseini, S.Y.; Sabahi, F.; Amini-Bavil-Olyaee, S.; Alavian, S.M.; Merat, S. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains. J. Virol. Methods 2006, 137, 298–303. [Google Scholar] [CrossRef]
Polymorphism | Primer Sequences 5′ → 3′ | Amplicon Size (bp) |
---|---|---|
R48G c.142C > G | F: GTGTCACGCCTTCTCCTCTC R: TGGCCACGCAAACGGGCCAGG | 204 |
A119S c.355G > T | F: ACGCTCCTGCTACTCCTGTC R: CCTTCCAGTGCTCCGAGTAG | 364 |
L432V c.1294C > G | F: CAGGCAGAATTGGATCAGGT R: CTCTGCTGGTCAGGTCCTTG | 310 |
N453S c.1358A > G | F: TGTCCTGGCCTTCCTTTATG R: GCCAGGATGGAGATGAAGAG | 324 |
Polymorphism | Fragment of the Gene after Amplification | Product Size (bp) | ||
---|---|---|---|---|
R48G c.142C > G | HpaII CCGG GTGTCACGCCTTCTCCTCTCTGTCCCCAGCATGGGCACCAGCCTCAGCCCGAACGACCCTTGGCCGC↓TAAACCCGCTGTCCATCCAGCAGACCACGCTCCTGCTACTCCTGTCGGTGCTGGCCACTGTGCATGTGGGCCAGCGGCTGCTGAGGCAACGGAGGCGGCAGCTCSGGTCCGCGCCCCCTGGCCCGTTTGCGTGGCCA | CC | CG | GG |
171 33 | 204 171 33 | 204 | ||
A119S c.355G > T | NaeI GCCGGC ACGCTCCTGCTACTCCTGTCGGTGCTGGCCACTGTGCATGTGGGCCAGCGGCTGCTGAGGCAACGGAGGCGGCAGCTCCGGTCCGCGCCCCCGGGCCCGTTTGCGTGGCCACTGATCGGAAACGCGGCGGCGGTGGGCCAGGCGGCTCACCTCTCGTTCGCTCGCCTGGCGCGGCGCTACGGCGACGTTTTCCAGATCCGCCTGGGCAGCTGCCCCATAGTGGTGCTGAATGGCGAGCGCGCCATCCACCAGGCCCTGGTGCAGCAGGGCTCGGCGCC↓GRCCTTCGCCTCCTTCCGTGTGGTGTCCGGCGGCCGCAGCATGGCTTTCGGCCACTACTCGGAGCACTGGAAGG | GG | GT | TT |
290 74 | 364 290 74 | 364 | ||
L432V c.1294C > G | OliI CACNNNNGTG CAGGCAGAATTGGATCAGGTCGTGGGGAGGGACCGTCTGCCTTGTATGGGTGACCAGCCCAACCTGCCCTATGTCCTGGCCTTCCTTTATGAAGCCATGCGCTTCTCCAGCTTTGTGCCTGTCACTATTCCTCATGCCACCACTGCCAACACCTCTGTCTTGGGCTACCACATTCCCAAGGACACTGTGGTTTTTGTCAACCAGTGGTCTGTGAATCATGACCCAST↓GAAGTGGCCTAACCCGGAGAACTTTGATCCAGCTCGATTCTTGGACAAGGATGGCCTCATCAGCAAGGACCTGACCAGCAGAG | CC | CG | GG |
228 82 | 310 228 82 | 310 | ||
N453S c.1358A > G | MwoI GCNNNNNNNGC TGTCCTGGCCTTCCTTTATGAAGCCATGCGCTTCTC↓CAGCTTTGTGCCTGTCACTATTCCTCATGCCACCA↓CTGCCAACACCTCTGTCTTGGGCTACCACATTCCCAAGGACACTGTGGTTTTTGTCAACCAGTGGTCTGTGAATCATGACCCACTGAAGTGGCCTAACCCGGAGAACTTTGATCCAGCTCGATTCTTGGACAAGGACGGCCTCAT↓CARCAAGGACCTGACCAGCAGAGTGATGATTTTTTCAGTGGGCAAAAGGCGGTGCATTGGCGAAGAACTTTCTAAGATGCAGCTTTTTCTCTTCATCTCCATCCTGGC | AA | AG | GG |
253 36 35 | 253 145 108 36 35 | 145 108 36 35 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dąbrowski, A.; Nowicki, M.; Budzyńska, A.; Suchodolski, J.; Ogórek, R.; Chabowski, M.; Przywara, K. Analysis of CYP1B1 Polymorphisms in Lung Cancer Patients Using Novel, Quick and Easy Methods Based on CAPS and ACRS-PCR Techniques. Int. J. Mol. Sci. 2024, 25, 6676. https://doi.org/10.3390/ijms25126676
Dąbrowski A, Nowicki M, Budzyńska A, Suchodolski J, Ogórek R, Chabowski M, Przywara K. Analysis of CYP1B1 Polymorphisms in Lung Cancer Patients Using Novel, Quick and Easy Methods Based on CAPS and ACRS-PCR Techniques. International Journal of Molecular Sciences. 2024; 25(12):6676. https://doi.org/10.3390/ijms25126676
Chicago/Turabian StyleDąbrowski, Adam, Maciej Nowicki, Aleksandra Budzyńska, Jakub Suchodolski, Rafał Ogórek, Mariusz Chabowski, and Katarzyna Przywara. 2024. "Analysis of CYP1B1 Polymorphisms in Lung Cancer Patients Using Novel, Quick and Easy Methods Based on CAPS and ACRS-PCR Techniques" International Journal of Molecular Sciences 25, no. 12: 6676. https://doi.org/10.3390/ijms25126676